Literature DB >> 19034737

Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence.

Jesse J Suh1, Helen M Pettinati, Kyle M Kampman, Charles P O'Brien.   

Abstract

Recently, we reported that naltrexone at 150 mg/day significantly decreased cocaine and alcohol use for men but not women with co-occurring cocaine and alcohol dependence. The present study is an exploratory investigation of predictors that explain the different gender responses to naltrexone, with a particular focus on differential predictors of treatment attrition. No significant predictors were associated with treatment discontinuation in men. Women, however, were more likely to discontinue treatment when reporting severe pre-treatment psychiatric problems or nausea while in treatment. Further research on the impact of pre-treatment and in-treatment gender differences with naltrexone is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034737      PMCID: PMC2657877          DOI: 10.1080/10550490802409074

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  39 in total

1.  A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.

Authors:  J Chick; R Anton; K Checinski; R Croop; D C Drummond; R Farmer; D Labriola; J Marshall; J Moncrieff; M Y Morgan; T Peters; B Ritson
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

2.  Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects.

Authors:  S S O'Malley; S Krishnan-Sarin; C Farren; P G O'Connor
Journal:  J Clin Psychopharmacol       Date:  2000-02       Impact factor: 3.153

3.  Gender differences in problem severity at assessment and treatment retention.

Authors:  C L Arfken; C Klein; S di Menza; C R Schuster
Journal:  J Subst Abuse Treat       Date:  2001-01

4.  Predictors of compliance with naltrexone among alcoholics.

Authors:  D J Rohsenow; S M Colby; P M Monti; R M Swift; R A Martin; T I Mueller; A Gordon; C A Eaton
Journal:  Alcohol Clin Exp Res       Date:  2000-10       Impact factor: 3.455

5.  Adverse effects of oral naltrexone: analysis of data from two clinical trials.

Authors:  C Oncken; J Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

Review 6.  Clinical uses of naltrexone: a review of the evidence.

Authors:  Vania Modesto-Lowe; Jeffrey Van Kirk
Journal:  Exp Clin Psychopharmacol       Date:  2002-08       Impact factor: 3.157

7.  Examining possible gender differences among cocaine-dependent outpatients.

Authors:  Conrad J Wong; Gary J Badger; Stacey C Sigmon; Stephen T Higgins
Journal:  Exp Clin Psychopharmacol       Date:  2002-08       Impact factor: 3.157

8.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

Authors:  S S O'Malley; A J Jaffe; G Chang; R S Schottenfeld; R E Meyer; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-11

9.  Preclinical and clinical studies on naltrexone: what have they taught each other?

Authors:  Janice Froehlich; Stephanie O'Malley; Petri Hyytiä; Dena Davidson; Conor Farren
Journal:  Alcohol Clin Exp Res       Date:  2003-03       Impact factor: 3.455

10.  A screening trial of amantadine as a medication for cocaine dependence.

Authors:  Steve Shoptaw; P C Kintaudi; Charles Charuvastra; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2002-05-01       Impact factor: 4.492

View more
  13 in total

1.  Missing data in alcohol clinical trials: a comparison of methods.

Authors:  Kevin A Hallgren; Katie Witkiewitz
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

2.  Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.

Authors:  Shelly F Greenfield; Helen M Pettinati; Stephanie O'Malley; Patrick K Randall; Carrie L Randall
Journal:  Alcohol Clin Exp Res       Date:  2010-07-20       Impact factor: 3.455

3.  Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram.

Authors:  Elise E DeVito; Theresa A Babuscio; Charla Nich; Samuel A Ball; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2014-10-20       Impact factor: 4.492

4.  Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Authors:  Judith Currier; Dawn Averitt Bridge; Debbie Hagins; Carmen D Zorrilla; Judith Feinberg; Robert Ryan; Ron Falcon; Alan Tennenberg; Joseph Mrus; Kathleen Squires
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

5.  Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?

Authors:  Peter D Friedmann; Donna Wilson; Edward V Nunes; Randall Hoskinson; Joshua D Lee; Michael Gordon; Sean M Murphy; Richard J Bonnie; Donna T Chen; Tamara Y Boney; Charles P O'Brien
Journal:  J Subst Abuse Treat       Date:  2017-02-22

6.  Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Authors:  Kelly E Dunn; Anthony Defulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Exp Clin Psychopharmacol       Date:  2012-12-03       Impact factor: 3.157

Review 7.  Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Authors:  Julia M A Sinclair; Sophia E Chambers; Celia J Shiles; David S Baldwin
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

8.  Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015.

Authors:  William S John; Li-Tzy Wu
Journal:  Drug Alcohol Depend       Date:  2017-09-18       Impact factor: 4.492

9.  Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.

Authors:  Breanne E Biondi; Cynthia A Frank; Ariadna Forray; Sandra A Springer
Journal:  Subst Abus       Date:  2021-03-22       Impact factor: 3.716

Review 10.  Ethanol actions on the ventral tegmental area: novel potential targets on reward pathway neurons.

Authors:  Chang You; Bertha Vandegrift; Mark S Brodie
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.